| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 6.316 | 21.927 | 41.481 | 49.080 | 73.842 | 90.628 | 100.917 | 125.492 | 150.170 | 152.019 |
| Total Income - EUR | 16.303 | 20.884 | 39.915 | 73.105 | 152.197 | 112.769 | 126.328 | 168.417 | 184.314 | 186.624 |
| Total Expenses - EUR | 34.575 | 26.054 | 52.623 | 84.517 | 152.828 | 85.952 | 91.271 | 117.921 | 119.795 | 136.047 |
| Gross Profit/Loss - EUR | -18.272 | -5.170 | -12.708 | -11.412 | -631 | 26.818 | 35.057 | 50.497 | 64.519 | 50.578 |
| Net Profit/Loss - EUR | -18.462 | -5.648 | -13.129 | -11.903 | -1.369 | 25.983 | 34.049 | 49.267 | 63.225 | 47.321 |
| Employees | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 |
Check the financial reports for the company - Renans Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 23.862 | 16.160 | 8.554 | 2.175 | 659 | 10.555 | 19.173 | 15.846 | 22.593 | 40.534 |
| Current Assets | 30.536 | 29.432 | 29.417 | 31.212 | 29.043 | 30.428 | 40.593 | 71.022 | 90.206 | 95.155 |
| Inventories | 12.552 | 13.926 | 11.190 | 22.808 | 13.378 | 24.497 | 30.032 | 38.924 | 44.261 | 39.824 |
| Receivables | 17.089 | 8.503 | 13.265 | 7.034 | 9.270 | 5.392 | 9.288 | 30.405 | 34.680 | 34.942 |
| Cash | 896 | 7.004 | 4.961 | 1.369 | 6.395 | 539 | 1.274 | 1.693 | 11.265 | 20.389 |
| Shareholders Funds | -56.676 | -61.746 | -73.830 | -84.378 | -84.113 | -56.536 | -21.233 | 27.968 | 91.108 | 120.893 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 111.227 | 107.462 | 111.954 | 117.964 | 113.898 | 97.847 | 81.496 | 59.258 | 22.118 | 15.363 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Renans Pharma Srl